Hormone Receptor-Positive Cancer

The FDA granted fast track designation to gedatolisib for treatment of certain patients with breast cancer.

Evaluating recurrence score and Ki67 better defined subsequent treatment for women with hormone receptor-positive, HER2-negative early breast cancer, according to study results presented at the virtual San Antonio Breast Cancer Symposium.